Archive for the ‘MOMENTUM’ Category

VisionTech Partners, Pearl Pathways Form Alliance to Fuel Growth in Indiana’s Life Sciences Startup Community

September 27, 2017

For Immediate Release

INDIANAPOLIS, Indiana (August 30, 2017) – – VisionTech Partners, the parent of Indiana’s most active angel investing group, and Pearl Pathways, a provider of life sciences product development services, have joined forces to fuel Indiana’s life sciences startup community, which includes biopharmaceutical, medical device and diagnostics technology.


The VisionTech Partners-Pearl Pathways alliance will focus on three essential goals. First, identify the most promising early stage/early growth companies for potential investment by VisionTech’s statewide network of angel investors. Second, connect entrepreneurs with individuals who have already achieved success in the life sciences and are willing to serve as mentors and business advisors. And finally, provide entrepreneurs with access to the highly specialized services required to negotiate the FDA approval process.


VisionTech Partners Executive Director Ben Pidgeon said both companies are eager to leverage their respective strengths through the alliance, which will formally launch Thursday, August 31, at VisionTech Angels’ “Pitch Night” in Indianapolis, featuring two life sciences startups.


“VisionTech Partners is extremely committed to growing Indiana’s life sciences industry and we’ve proven ourselves to be a valuable contributor to this effort as a source of financial and human capital. Of the 24 portfolio companies our angel network has invested in, 10 are in the life sciences and healthcare space; it’s definitely a sweet spot,” said Pidgeon.


“The alliance with Pearl Pathways will not only ensure a high quality deal flow, it will also help us make better investment decisions. Most of these companies must secure FDA approval in order to commercialize their drug, device or diagnostic tool. Pearl Pathways will, in effect, be VisionTech Partners’ resident expert on all things FDA,” he added.


Based in Indianapolis, Pearl Pathways is a life science product development services company that provides clinical research, regulatory, quality compliance, and independent review board services to life sciences companies. Among Pearl Pathways’ clientele are five of the top 20 medical device companies and six of the top 11 pharmaceutical companies in the world.


The balance of their business, said President and CEO Diana Caldwell, is startup companies with pre-commercialization technology that need access to early stage or “seed” funding provided by groups like VisionTech Partners.


“VisionTech Partners is unique in the angel investing space. Yes, they are a source of capital, but more importantly, they have deep experience and success in the life sciences industry. They also have a chapter composed entirely of physicians. These are the people who are around medical technology on a daily basis and have knowledge and insight few investors have. Partnering with VisionTech will not only open doors for our clients, startup companies across Indiana will benefit from the combined talents and resources of our two companies,” Caldwell said.


About VisionTech Partners I VisionTech Angels

Founded in 2008, VisionTech Partners is a privately held company focused on linking investors to high-potential early-stage companies. Headquartered in Indianapolis, among the nation’s most vibrant innovation regions, VisionTech is where inventors, entrepreneurs, investors, universities, and strategic partners convene to share, fund, and launch novel technologies. VisionTech Angels has chapters in Bloomington, Fort Wayne, Indianapolis, Lafayette, and an Affinity chapter, AngelBom.


About Pearl Pathways.

Founded in 2010, Pearl Pathways is a comprehensive life science product development consulting services company with expertise in regulatory, quality compliance, and clinical trial services including an AAHRPP accredited commercial IRB, Pearl IRB. Pearl Pathways works with clients’ clinical teams, in-house regulatory experts, the quality compliance specialists, quality auditors, and the senior leadership team to get life saving diagnostics and therapeutics on the market sooner.

Contact: Melanie Lux,, 803.331.4794

Contact: Waylon Wright,, 317.602.5479


August 2017 Life Sciences Lunch

August 28, 2017

LSL Banner

The Indiana Health Industry Forum and Barnes & Thornburg LLP partner to present a monthly seminar series on critical issues in the life sciences. Each month, at lunch, a policymaker or a panel in the field of life science will be available to answer questions concerning the major challenges and opportunities in the industry. We hope you will join us.


Tech Transfer Driving Indiana’s Innovation Ecosystem

The Technology Transfer Offices at Indiana’s leading research universities are churning out new technologies and start-up companies like never before.  Finding new ways to support and develop early stage innovations and then matching those with the right development partners takes time, creativity, and a network of partnerships with industry and funders.  Please join us as we hear from a panel of research university representatives highlighting some of their latest life science technologies and explore how they are gearing up to smooth out the translational process!

Deborah Pollack-Milgate, Partner
Barnes & Thornburg LLP

Brooke Beier, Ph.D.
Purdue Research Foundation
Executive Director of Purdue’s Office of Technology Commercialization.

Karen Imgrund Deak, Ph.D.
Commercialization Specialist
IDEA Center
University of Notre Dame

Simon Atkinson, Ph.D.
IUPUI Interim Vice Chancellor for Research, Biology

New ShareVault White Paper: What’s the role of Non-Immuno Oncology in an Immuno Oncology World?

August 10, 2017

“New ShareVault White Paper:  ” What’s the role of Non-Immuno Oncology in an Immuno Oncology World?”

This white paper discusses the role of non-immuno-oncology therapies for cancer in a world where immuno-oncology is playing a greater role.


The clinical success of checkpoint inhibitors has made Immuno-Oncology an amazingly “hot” area for pharmaceutical and biotech deal making.  With checkpoint antibodies seen as backbones for combination therapy in cancer, many in Oncology are asking:

• What is the role of non-IO in an IO world and can you partner a non-IO opportunity?

• Is there still room for new anticancer agents that are not working in IO models?

• Are drug candidates evaluated with the assumption that everything will eventually be used in combination with IO agents?  Or are there indications or mechanisms for which IO will never be important?  Should I pursue combinations with IO?

• What kinds of mechanisms are attractive in non-IO?  What data and models will big pharma want to see?   Do I need to run experiments with their molecule?  Are there certain tumor types that are particularly attractive?

• Is it too late to try to compete in the crowded space of combination with PD1 antibodies?  What other IO agents are likely to backbones of oncology franchises?

• What will make my non-IO drug candidate compelling for partners and investors?

Download the white paper at this link.

IHIF Signs Partnership Agreement With Scottish Lifesciences Association

May 17, 2017

 Builds New Market Opportunities for State Industry Members

Contact: Kristin Jones, IHIF, +1-317-752-9809

(Indianapolis,IN USA and Edinburgh, Scotland UK- May 16, 2017) — The Indiana Health Industry Forum (IHIF) and the Scottish Lifesciences Association (SLA) have signed a Memorandum of Understanding to share member benefits between the two organizations.  IHIF and SLA share the same essential vision with regards to creation and maintenance of an environment that nurtures and supports life sciences companies.  The objectives are to foster innovation and valuable, dynamic links between US-based member companies of IHIF and Scotland-based member companies of SLA.


According to Scott Johnstone, CEO of the SLA, “IHIF and SLA intend to represent the USA and EU to each other as practical for the mutual benefit of our organizations and our member companies.  Through this relationship, we intend to increase the visibility, sales, investment, regulation, and innovation prospects for our member companies”.


Both organizations are members of the multi-state Turnpike Partnership, an innovation-driven network of resources and organizations built to support and enhance the life sciences industry. Scotland is a key international partner with a life sciences cluster of similar size and scope to Indiana’s.


Building on an already strong trade relationship, “IHIF and SLA were able to come together through the Turnpike Partnership and build an alliance that will directly benefit our members”, said Kristin Jones, President and CEO of IHIF.  “The partnership with SLA is a further expansion of our international network and will give our members strategic access to UK and European markets at a time of dynamic change.  We also look forward to working with members of SLA as they build their business networks and explore opportunities in the U.S.”


The MOU was signed at the 2017 Derby Summit, an annual event for the Kentucky Life Sciences Council.  The Scottish delegation also visited Boston and IHIF representatives attended the May 11 Spring Members Meeting for the SLA in Glasgow, Scotland.


About SLA

With 135 member companies and organisations, the SLA is the voice of Scotland’s vibrant life sciences industries to investors, NHSScotland, the Scottish and UK Governments, and the wider community.  The SLA is driven by and network with its members through 14 Special Interest Groups and 4 sub-groups.  The SLA helps to grow members’ businesses, and engage with the NHS and Government to grow the life sciences sector in Scotland.


For more information:


About IHIF

IHIF is a statewide trade association representing Indiana’s health science business community.  The diverse members of the Indiana Health Industry Forum generate the collective voice of the state’s health and life science industry.  Our mission is to connect key stakeholders to: enhance business networks, advocate for member interests, develop workforce skills, and provide strategic vision in the interest of growing the state’s health industry economy and reputation.


For more information:


Kristin Jones (IHIF) and Scott Johnstone (SLA) sign agreement to trade member services.


FAST BioMedical Raises $8 Million as part of Series A2 Financing Round

May 3, 2017

Carmel, Indiana – May 3, 2017 – FAST BioMedical, Inc. today announced it has secured $8 million of additional financing.  $5 million comes from a Series A2 Financing led by one new investor, F&M Investment Office.  This financing augments $3 million of grant funding received as a competing renewal award from the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health.  The proceeds will primarily be used to advance clinical trials of the company’s technology as well as to hire additional talent and advance the company’s global patent portfolio.

“This financing is an important and validating step to continue our progress,” said Joe Muldoon, FAST BioMedical Chief Executive Officer.  “We have already begun adding talent to the team, and are excited about their ability to immediately add value”

“FAST BioMedical has enormous potential to serve large unmet medical needs with its innovative technology,” said Mr. McClure, President of F&M Investment Office.  “We are delighted to partner with them, and see great promise in the ability to favorably impact critical patient care. ”

About FAST BioMedical

FAST BioMedical is a private, clinical-stage medical technology company in Carmel, Indiana.  The company’s globally patented first-in-class technologies directly measure blood volume and kidney function in a clinically viable way.  This has the potential for profound impact on care of congestive heart failure, major surgery, sepsis, critical care, and kidney disease patients.   The company has been financially supported by the NIH, Elevate Ventures, the Indiana 21st Century Fund, Rose-Hulman Ventures, BioCrossroads, Indiana University Medical Group, The Purdue Foundry Fund, Ellipsis Ventures, StepStone Partners, and private family office investors. The FDA has determined the company’s technology met the requirements for an Expedited Review.

These products are investigational and not yet approved for human use.

For more information, please visit

MOMENTUM Final Pitch Presentations 12-9-15

February 19, 2016

The three companies selected to participate in the first cycle of IHIF’s MOMENTUM Team Mentorship Program presented their final pitch presentations on December 9th, 2015.  You may view the video below:

Presenting companies were:

  • Eric Graban, Quarry BioScience (begins at 5:10)
  • Erik Robinson, Sintact Medical Systems (begins at 19:00)
  • Aleks Davis, B2S Laboratories (begins at 33:12)

For more information on MOMENTUM, becoming a sponsor, mentor, or mentee company, please visit

Thank you to our Cycle 1 Sponsors:

Indiana CTSI –

Barnes & Thornburg LLP

The Office of Small Business and Entrepreneurship (OSBE) –

Ivy Tech/Gayle & Bill Cook Center for Entrepreneurship –


IHIF Welcomes Mindray for First Discovery Days Program

January 7, 2016


Momentum Logo June 2014

Discovery Days

February 17-18, 2016

Mindray logo


The Indiana Health Industry Forum is pleased to announce that we have finalized dates for a company visit to Indiana by Mindray.   IHIF will be hosting company representatives here in Indianapolis on February 17th -18th for our first Discovery Days program!  Mindray representatives are interested in meeting Indiana businesses working in two areas: 1) in-vitro diagnostics and 2) assistive technologies, including health IT applications.  They are interested in meeting with both companies with established products looking to expand their market into China as well as identifying novel technologies that could use a developmental partner.   Mindray offers investment capital, assistance with CFDA approval, and joint venture opportunities.

About Mindray Medical International

Mindray was founded in 1991 in Shenzhen, China, with a mission to deliver high-quality, competitively priced medical devices to make healthcare more accessible and affordable around the world. Over the last 17 years, we have become a leading developer, manufacturer and marketer of medical devices in China with a rapidly growing international presence. We are expanding our distribution network, sales and sales support staff to bring our products closer to end users. We currently have 29 local sales and service offices in China, as well as sales and service subsidiaries in Amsterdam, Istanbul, London, Mexico City, Moscow, Mumbai, Sao Paulo, Seattle, Toronto and Vancouver.   For more information, please visit

Apply to meet

If you have technologies or know of companies that may be interested in meeting with Mindray’s technology development representatives, please let us know!  IHIF is working to identify a pool of potential companies/technologies and then, working with Mindray, we’ll put together a short list of invitees to a 1-on-1 meeting with them here in Indianapolis.   Please submit a short (1 page) description of the company/technology to get things started.    Please submit descriptions to IHIF at   We will begin notifying accepted applicants by January 20th.

Boehringer Ingelheim Day with MassBio

September 23, 2015

Boehringer Ingelheim Day with MassBio

2:00 – 7:30pm

MassBio and Catalyst restaurant at 300 Technology Square, Cambridge, MA 02139

October 8th, 2015


The Indiana Health Industry Forum has been invited to submit member profiles for consideration in the Boehringer Ingelheim Pharma Days program.  This event will be held in Boston, October 8th and is organized by MassBio – IHIF’s counterpart organization in Massachusetts.  If you would like to be considered for a one-on-one meeting with Boehringer Ingelheim, please submit a one-pager describing your program of interest to Kristin Jones at IHIF ( by September 30th.  Please do not disclose confidential information. If selected, you must be able to travel to Boston on October 8th to participate in the meetings.


Please join us on Thursday, October 8th, 2015 for a private meeting and reception with a select group of MassBio members and senior leaders from Boehringer Ingelheim.

Boehringer Ingelheim will provide an overview of its Research & Development organization, Venture fund, therapeutic areas of interest and models for early and late stage licensing partnerships. There will be an opportunity to request one–to-one meetings. A poster competition and pitch contest will take place and a networking reception will follow the program. An innovation prize will be awarded to the winning start-up from the pitch contest at the reception.

One-on-one meetings may be requested by participants.

Boehringer Ingelheim will have teams within the following areas participating in one-on-one meetings: CNS, Oncology, Cardiometabolic, Immunology, Respiratory, Hearing loss, Microbiome, Regenerative medicine and Gene medicine.  For more details, see list below.


2:00 – 3:00pm               Registration and Poster presentation vote for Innovation Prize

Attendees will receive Massbio Dollars to invest into the top 3 most innovative technologies presented.


3:00 – 3:05pm               Welcome by MassBio Robert K. Coughlin, President and CEO at MassBio


3:05 – 3:30pm            Boehringer Ingelheim Partnering – Working Together for Better Health

  • Paola Casarosa, Corp VP, Business Development & Licensing/ Prescription Medicines


3:30 – 4:00pm            Discovery Research and External Innovation

  • Clive Wood, Corp Senior VP, Discovery Research


4:00 – 4:30pm            Boehringer Ingelheim Corporate Venture Fund

  • Frank Kalkbrenner, VP, Head of the Boehringer Ingelheim Venture Fund


4:30 – 5:00pm               Innovation Prize pitches and judging


5:00 – 5:30pm               Boehringer Ingelheim closing remarks and Q&A


5:30 –7:00pm                Reception – Catalyst
Innovation Prize winner will be announced at the reception


This event, part of the MassBio Pharma Day Series, will provide a great opportunity to network with Boehringer Ingelheim licensing and therapeutic area leaders and learn how a biopharmaceutical company evaluates external research and approaches licensing and partnerships.


Current Areas of Interest:


    • Central Nervous System
  • Alzheimer’s disease
  • Schizophrenia (focus: negative symptoms and/or cognitive impairment)
  • Depression (focus: treatment-resistant depression)
  • Impulse control disorders

Out of scope: Monoamine uptake inhibitors or monoamine receptor modulators, Compounds with undefined mechanism of action

    • Oncology
  • For clinical stage opportunities: Focus on lung cancer and haematology – irrespective of the MoA
  • Up to IND-ready stage:
  • Cancer cell -directed therapies
    • Growth signaling
    • Apoptosis regulation
    • Epigenetic regulation
    • Protein homeostasis
    • Additional areas of focus will emerge from scientific breakthroughs in cancer biology (e.g. genome integrity, splicing, protein translation, stem cell / developmental pathways, miRNAs)
  • Immune cell -directed therapies
    • Immune cell re-activation
    • Immune cell re-direction
    • Immune cell priming
    • Increased focus in the future will be on lymphocyte trafficking


  • Immunology
    • Crohn’s disease and ulcerative colitis
    • Systemic lupus erythematosus (including lupus nephritis)
    • Rheumatologic disorders such as RA (limited to mechanisms that show superior efficacy compared to current standard of care) and spondyloarthritis
    • Systemic sclerosis-scleroderma

Out of Scope: Microbial therapeutics and Gene therapy


  • Cardiometabolic
    • Chronic Kidney Diseases and Diabetic Nephropathy
    • Diabetic Retinopathy
    • NASH (Nonalcoholic steatohepatitis) and liver fibrosis
    • Obesity (CV-benefit and patient relevant weight loss >10%)
    • Type 2 Diabetes (evidence for disease modification, CV-risk reduction and/or significant weight reduction)


  • Respiratory
    • Chronic Obstructive Pulmonary Disease
    • Asthma
    • Interstitial Pulmonary Fibrosis
    • Cystic Fibrosis
    • Acute Lung Injury or Acute Respiratory Distress Syndrome


  • Research Beyond Borders
  • Microbiome:
    • Novel bacteria/bacterial products and their causal role in human health & disease (esp. related to autoimmune, CNS, oncology  and cardiometabolic disorders)
    • Microbiome triggers which impact host immune/inflammatory response & barrier function Depression (focus: treatment-resistant depression)
    • Elucidation of associated pathways & discrete targets (both host & microbiome-derived) for therapeutic intervention
  • Regenerative Medicine:
    • Molecular understanding of mechanisms involved in tissue degeneration
    • New targets or methods for identifying targets that are implicated in the mobilization and/or differentiation of endogenous stem cells/progenitor cells
    • Approaches that may modulate muscle/bone/cartilage degeneration, and/or neurodegeneration
  • Gene Therapy:
    • Rare diseases with high unmet medical need as entry, enabling BI to become a leader in the field; including proprietary assets available for potential partnering
    • Technology platform development, focusing on inducible system for regulatable expression of therapeutic products in the context of AAVs, ensuring applicability of gene therapies in nonlife-threatening diseases
  • Hearing Loss:
    • Understanding of mechanisms involved in hearing loss and approaches with potential to restore hearing or reduce loss
  • Age-related, as well as noise and drug-induced hearing loss




Boehringer Ingelheim Attendees:


Dr. Paola Casarosa, Corp. VP, Bus. Dev. & Licensing/Prescription Medicines

Dr. Monica Cheng, Global Licensing, Cardiometabolic Diseases, Bus. Dev. & Licensing/Prescription Medicines

Dr. Laurie Churchill, Global Head Immunology, Bus. Dev. & Licensing/Prescription Medicines

Dr. Henri Doods, VP, Research Beyond Borders

Dr. Jay Fine, Vice President & Global Therapeutic Area Head Immunology and Respiratory Diseases Research

Dr. Christine Grygon, Executive Director, Bus. Dev. & Licensing/Prescription Medicines

Dr. Martin Heidecker, Head of Venture Fund USA

Dr. Jullian Jones, Global Licensing, Oncology

Dr. Frank Kalkbrenner, VP, Venture Fund

Dr. Cyrille Kuhn, Executive Director, Head of Research Beyond Borders

Dr. Michael Mark, Global Head CardioMetabolic Diseases Research

Dr. Klaus Mendla, Global Head CNS, Bus. Dev. & Licensing/Prescription Medicines

Mr. Imran Nasrullah, Innovation Sourcing, Bus. Dev. & Licensing/Prescription Medicines

Dr. Chad Nivens, Global Head Respiratory, Bus. Dev. & Licensing/Prescription Medicines

Mr. Andrew Owenson, Corp. SVP, Therapeutic Area Head Respiratory

Dr. Michel Pairet, Corp. SVP, R&D non-clinical

Dr. Glyn Parkin, Corp. SVP, Therapeutic Area Head Cardiometabolic Diseases

Dr. Mark Pearson, VP, New Therapeutics Concept Discovery

Dr. Jan Poth, Therapeutic Area Head Immunology & Vice President Marketing, Pipeline Products

Mr. Ralph Mark, Director, External Partnerships and Financial Strategy

Dr. Juergen Reess, Therapeutic Area Head CNS

Dr. Oliver Reuss, Head of Business Model & HealthCare Innovation

Dr. Ioannis Sapountzis, Global Head Oncology, Bus. Dev. & Licensing/Prescription Medicines

Prof. Dr. Gerd Schnorrenberg, Senior Executive Advisor, R&D non-clinical

Dr. Margrit Schwarz, VP, Cardiometabolic Diseases Research

Dr. Peter Seither, Senior Manager, Scientific Collaborations

Dr. Bernd Sommer, Head of CNS Research

Dr. Georg van Husen, Therapeutic Area Head Cardiovascular

Dr. Clive Wood, Corp. SVP, Discovery Research

Dr. Johannes Zanzinger, Global Head Cardiometabolic Diseases, Bus. Dev. & Licensing/Prescription Medicines


IHIF Announces MOMENTUM Program Manager

August 17, 2015

Advances Regional Partnership with Kentucky Counterpart

Momentum Logo June 2014

August 17, 2015 (INDIANAPOLIS, IN AND LOUISVILLE, KY) – The Indiana Health Industry Forum (IHIF) is pleased to announce that Andrew Steen will be serving as the Program Manager, Regional Innovation Services in a joint role with the Kentucky Life Sciences Council (KLSC), IHIF’s counterpart organization.  Steen will manage the first cycle of the MOMENTUM:Team Mentorship program, the leading piece of IHIF’s newly introduced mentorship initiative.  He will also be responsible for development of a one-year work plan for a joint state initiative to leverage the region’s life science academic, entrepreneurial, and commercial resources.

Steen has spent the past 15 years working within an academic medical center, principally focused on life science commercialization efforts. He was most recently the Interim President and CEO of MetaCyte Business Lab LLC, a subsidiary of the University of Louisville Foundation, Inc. During his time at MetaCyte Andy worked with scientists and clinicians to create companies, often functioning as part of the founding entrepreneurial team. Andy has built a significant industry network which he is able to leverage on behalf of MOMENTUM participants.

“We are incredibly lucky to have someone with Andy’s extensive background and experience leading this Cycle of MOMENTUM”, said Kristin Jones President and CEO of the Indiana Health Industry Forum.  “Having him on board with the program puts our mentors and entrepreneurs ahead of the game.  We are also delighted to be able to partner with the KLSC to build out a more cohesive regional strategy to better leverage and support entrepreneurs, academia, and industry.  MOMENTUM fits well with this broader strategy and this partnership should serve as a model to include other states as we go forward”.

Dr. Kyle Keeney, President and CEO of the KLSC said, ”this initiative is all about making it easier to connect ideas, people, and resources in the most efficient and effective ways possible.  The Kentucky-Indiana relationship is strong and both states can only benefit from greater knowledge of each other’s assets.  Andy Steen is now uniquely positioned to bring that vision to fruition. We couldn’t be more pleased to be working with IHIF on building a system that supports entrepreneurs in both states”.

The first 10-week Cycle of MOMENTUM:Team Mentorship will begin in September 2015 and features mentee companies B2S Labs, Sintact Medical Systems, and Reclaim Rx.  The program is being supported by CTSI, Barnes & Thornburg, The Indiana Office of Small Business and Entrepreneurship (OSBE)/ISBDC and the Gayle and Bill Cook Center for Entrepreneurship at Ivy Tech, Bloomington.  If you would like to learn more about becoming a MOMENTUM:Mentor or program sponsor, please visit


About IHIF

The Indiana Health Industry Forum (IHIF) is a statewide trade association representing members of Indiana’s health science business community.  The diverse members of IHIF generate the collective voice of the state’s health and life science industry.  Our mission is to connect key stakeholders to: enhance business networks, advocate for member interests, develop workforce skills, and provide strategic vision in the interest of growing the state’s health industry economy and reputation.  For more information and to become a member, please visit

About KLSC

The mission of the Kentucky Life Sciences Council is to provide advocacy and commercialization support that promote the life science community in Kentucky. For more information please see


MOMENTUM:Mentor Networks is a comprehensive set of programs designed to support Indiana’s health science sector and better tie industry, our research community, and our entrepreneurs together.  The programs will encourage earlier interaction between industry and investigators, provide earlier feedback on ideas and company development, and encourage later stage entrepreneurial growth and development.  To learn more, please visit

IHIF Announces First MOMENTUM:Team Mentorship Class

August 12, 2015

Thanks to Cycle I Sponsors: CTSI, OSBE/ISBDC, Barnes & Thornburg, and Ivy Tech

MOMENTUM:Mentor Networks is a comprehensive set of programs designed to support Indiana’s health science sector and better tie industry, our research community, and our entrepreneurs together.  The programs will encourage earlier interaction between industry and investigators, provide earlier feedback on ideas and company development, and encourage later stage entrepreneurial growth and development.

Momentum Logo June 2014

For Immediate Release

Contact: Kristin Jones, IHIF, 317-686-0994


August 13, 2015 (INDIANAPOLIS, IN)  – The Indiana Health Industry Forum (IHIF) is pleased to announce that the first class of mentee companies has been accepted into its MOMENTUM:Team Mentorship Program.  The companies participating in the first 10-week Cycle include: B2S Labs, Reclaim Rx, and Sintact Medical Systems.

The entrepreneurs will first present their companies to the MOMENTUM mentors, invited investors, steering committee, and IHIF Board of Directors at a First Pitch event scheduled for September 1.  Following the First Pitch, the companies will be matched with mentor teams and MBA student Project Managers to begin a 10-week session and conclude with a Final Pitch in December.

About the Companies:

B2S Labs (R. Aleks Davis, CEO) defines itself as a biotherapeutic enablement company, offering improved analytical methods and outcomes for companies involved in the development of biotherapeutic drugs and diagnostics. Our mission is to leverage extensive expertise in bioanalytical methods development to provide superior custom reagent products and services that are tailored to our clients’ needs, and to manage these products and services for clients throughout the drug development process.

Reclaim Rx (Eric Graban, Founder/CEO) offers protein analysis and imaging using a mass spec based covalent labeling process.  Data from our technology can provide insight into protein structure changes or binding interactions that would be difficult to obtain otherwise.

Sintact Medical Systems, Inc. (Erik Robinson, Ph.D., CEO) develops non-resorbable films that separate adjacent organs and prevent them from adhering to each other after surgery.

“On behalf of IHIF and the MOMENTUM Steering Committee, we are thrilled to announce our first class of Mentee companies for the MOMENTUM: Team Mentoring program.  B2S Labs, Reclaim Rx, and Sintact Medical Systems are an ideal group to work with and our mentors are ready and committed to help”, said Kristin Jones, President and CEO of the Indiana Health Industry Forum.  “MOMENTUM is the type of program that moves Indiana into an elite tier of life science clusters and leverages the needs and interests of our diverse industry base.  We are especially grateful to our sponsors and supporters, the Indiana Clinical and Translational Sciences Institute (CTSI), Barnes & Thornburg, The Gayle and Bill Cook Center for Entrepreneurship at Ivy Tech, and the Indiana Office of Small Business and Entrepreneurship (OSBE)/ISBDC.”

To find out more about MOMENTUM or apply to become a mentor, mentee, or MBA student project manager, please visit the MOMENTUM website at


About IHIF

The Indiana Health Industry Forum (IHIF) is a statewide trade association representing members of Indiana’s health science business community.  The diverse members of IHIF generate the collective voice of the state’s health and life science industry.  Our mission is to connect key stakeholders to: enhance business networks, advocate for member interests, develop workforce skills, and provide strategic vision in the interest of growing the state’s health industry economy and reputation.  For more information and to become a member, please visit